إعلان
إعلان

KRRO

KRRO logo

Korro Bio, Inc. Common Stock

8.48
USD
برعاية
+0.22
+2.72%
٠٧ يناير, ١٦:٠٠ UTC -5
مغلق
exchange

بعد الإغلاق

8.48

0.00
-0.06%

تقارير أرباح KRRO

النسبة الإيجابية المفاجئة

KRRO تفوق 13 من 25 آخر التقديرات.

52%

التقرير التالي

بيانات التقرير القادم
١٦ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$708.17K
/
-$2.16
التغير الضمني من Q3 25 (Revenue/ EPS)
-35.03%
/
+12.50%
التغير الضمني من Q4 24 (Revenue/ EPS)
-68.82%
/
-4.00%

Korro Bio, Inc. Common Stock earnings per share and revenue

On ١٢ نوفمبر ٢٠٢٥, KRRO reported earnings of -1.92 USD per share (EPS) for Q3 25, beating the estimate of -2.64 USD, resulting in a 27.43% surprise. Revenue reached 1.09 مليون, compared to an expected 589.78 ألف, with a 84.81% difference. The market reacted with a -79.31% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 12 المحللين forecast an EPS of -2.16 USD, with revenue projected to reach 708.17 ألف USD, implying an زيادة of 12.50% EPS, and نقصان of -35.03% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Pharmaceuticals Inc. Common
Report Date
٢٦ ديسمبر ٢٠٢٥ إلى ربع سنوي4 25
تقدير
-$0.49
الفعلي
-
مفاجئة
-
الأسئلة الشائعة
For Q3 2025, Korro Bio, Inc. Common Stock reported EPS of -$1.92, beating estimates by 27.43%, and revenue of $1.09M, 84.81% above expectations.
The stock price moved down -79.31%, changed from $31.42 before the earnings release to $6.50 the day after.
The next earning report is scheduled for ١٦ مارس ٢٠٢٦.
Based on 12 المحللين, Korro Bio, Inc. Common Stock is expected to report EPS of -$2.16 and revenue of $708.17K for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان